Based on its proprietary platform, Biomunex is developing immunotherapies for several cancer types.

Its modular bispecific antibody BiXAb platform enables the company to develop drug candidates with anti-tumor potential, manufacturability and optimal drug-like properties.

The company has two lead candidates, BMX-002, which has demonstrated superior in vivo efficacy in pancreatic cancer, and BMX-101, an immunotherapeutic being developed for a hematological malignancy.